BKM Wealth Management LLC Purchases 2,757 Shares of Smith & Nephew plc (NYSE:SNN)

BKM Wealth Management LLC grew its stake in shares of Smith & Nephew plc (NYSE:SNN) by 17.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,240 shares of the medical equipment provider’s stock after acquiring an additional 2,757 shares during the quarter. BKM Wealth Management LLC’s holdings in Smith & Nephew were worth $463,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Scharf Investments LLC increased its holdings in shares of Smith & Nephew by 0.5% during the first quarter. Scharf Investments LLC now owns 2,996,264 shares of the medical equipment provider’s stock valued at $75,985,000 after acquiring an additional 15,930 shares in the last quarter. American Century Companies Inc. increased its holdings in Smith & Nephew by 343.5% in the 3rd quarter. American Century Companies Inc. now owns 2,364,037 shares of the medical equipment provider’s stock worth $58,557,000 after buying an additional 1,830,965 shares during the period. Goldman Sachs Group Inc. increased its holdings in Smith & Nephew by 3.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,343,712 shares of the medical equipment provider’s stock worth $36,656,000 after buying an additional 44,445 shares during the period. Brandes Investment Partners LP acquired a new position in Smith & Nephew in the 4th quarter worth approximately $29,884,000. Finally, Wells Fargo & Company MN increased its holdings in Smith & Nephew by 20.9% in the 4th quarter. Wells Fargo & Company MN now owns 1,003,050 shares of the medical equipment provider’s stock worth $27,363,000 after buying an additional 173,448 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analyst Ratings Changes

SNN has been the topic of several research reports. UBS Group upgraded shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a report on Wednesday, June 5th. StockNews.com lowered Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 13th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Smith & Nephew Trading Down 1.1 %

Smith & Nephew stock opened at $24.51 on Tuesday. The company has a current ratio of 1.77, a quick ratio of 0.72 and a debt-to-equity ratio of 0.44. Smith & Nephew plc has a 12 month low of $21.52 and a 12 month high of $31.31. The stock’s 50 day simple moving average is $25.17 and its two-hundred day simple moving average is $26.26. The firm has a market cap of $10.72 billion, a PE ratio of 11.96, a P/E/G ratio of 1.10 and a beta of 0.80.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.